Lipotope Holdings has developed a groundbreaking technology, BioShuttle™, a patent-pending delivery platform that revolutionizes the way bioactive compounds are transported across biological barriers.
For decades, transdermal drug delivery has been considered the "holy grail" of medicine—an elusive goal that promises to revolutionize patient care by enabling the administration of large molecules (like proteins, mRNA, and DNA) without needles, invasive procedures, or clinical supervision.
At the forefront of this medical revolution is Dr. Michael Oda, the visionary behind Lipotope Holdings' BioShuttle™ technology. Built on the foundation of our patent pending Protein Stabilized Liposomes (PSLs), BioShuttle™ is a next-generation drug delivery system designed to overcome the limitations of conventional lipid nanoparticles.
BioShuttle™'s PSLs are advanced, patent-pending nanoparticles stabilized by a proprietary protein that acts as a "molecular key," unlocking the body's natural protective barriers. This enables bioactive compounds to be delivered rapidly and safely—not just across the skin, but also via intranasal, pulmonary, and parenteral routes.
BioShuttle™ ensures efficient release, enabling micro-dosing at levels up to 1,000-fold lower than standard therapies. This reduces side effects while maintaining or enhancing therapeutic efficacy.
PSLs can be "tuned" for specific outcomes—whether that's rapid, localized action or sustained systemic release. They can even be programmed to self-disassemble after delivering their cargo, minimizing residual presence in the body.
BioShuttle™ formulations maintain their potency for up to two years at room temperature, addressing a critical limitation of traditional nanoparticles that degrade rapidly.
Beyond transdermal delivery, PSLs are effective for intranasal delivery (targeting the brain via the trigeminal nerve), pulmonary administration, and even injectable formulations when needed.
BioShuttle™ isn't just an incremental improvement—it's a paradigm shift in drug delivery. From revolutionizing how we treat chronic conditions to transforming consumer health products, Lipotope's technology bridges the gap between scientific possibility and real-world application. Whether it's enabling needle-free vaccines, enhancing athletic recovery, managing chronic pain, or delivering life-saving medications directly to the brain, BioShuttle™ is poised to redefine what's possible in medicine.





At Lipotope Holdings, our mission is to revolutionize health, wellness, and performance through our patent-pending BioShuttle™ delivery platform. We've developed a portfolio of five market-ready formulations, each designed to meet unmet needs in their respective categories. These products are available for white-label partnerships, allowing companies to integrate cutting-edge science into their brands with speed and efficiency.
In addition to these formulations, we actively seek partnerships with companies looking to enhance the efficacy of their own active ingredients through our BioShuttle™ technology. Our platform's versatility enables rapid, stable, and highly bioavailable delivery across multiple routes—including transdermal, intranasal, and parenteral—making it an ideal solution for a wide range of therapeutic applications.
A powerful, non-invasive alternative to traditional weight loss drugs like semaglutides. This nasal spray supports appetite control, reduces cravings, and regulates metabolism—all without injections.
Designed to address anxiety-related insomnia and PTSD-induced sleep disturbances, this fast-acting spray promotes restful sleep without the dependency risks of traditional sedatives.
A transdermal, anti-inflammatory product that provides rapid relief (within seconds) for inflammation-based pain conditions like arthritis, fibromyalgia, migraines, and sports injuries.
A topical formulation proven to enhance physical performance by up to 10%, reduce lactic acid buildup, and accelerate recovery times. It's a game-changer for both elite athletes and fitness enthusiasts.
Designed to address intimacy issues related to hormonal changes, this formulation improves libido, arousal, and overall sexual well-being in postmenopausal women.
Beyond our ready-to-market products, we collaborate with companies seeking to enhance their existing products using our BioShuttle™ delivery technology. Whether you're looking to:
...we can provide customized formulations tailored to your needs.
If you're a brand looking to differentiate with scientifically advanced products, or a company with an active ingredient in need of a superior delivery system, Lipotope Holdings is your ideal partner.
Contact our partnership team to explore white-label opportunities, co-development partnerships, or custom formulation solutions powered by BioShuttle™.
Email: info@Lipotope.net
Schedule a consultation to discuss how BioShuttle™ technology can enhance your product portfolio.
About Lipotope Holdings: Pioneering Next-Generation Drug Delivery